http://www.scribd.com/people/view/83600-medgadget This a feed for documents on Scribd written by medgadget 30 Wed, 21 May 2008 18:01:08 GMT Wed, 21 May 2008 18:01:08 GMT http://www.scribd.com/doc/3042648/192 PROFILE 3D™ Annuloplasty System for Mitral Repair In-Service Guide *PROFILE 3D™ Annuloplasty System l In-Service PROFILE 3D™ COMPONENTS Each Profile 3D™ Ring package contains a single annuloplasty ring assembly consisting of a ring mounted on a holder, packaged in sterile, double-aseptic transfer trays. Handle Holder Retention Suture Trigonal Markers Holder Retention Suture Mid-Posterior Marker Holder Ring *PROFILE 3D™ Annuloplasty System l In-Service SIZING THE ANNULUS To determine the proper Profile 3D™ Ring size to be used requires measuring both the distance between the trigon Wed, 21 May 2008 18:01:08 GMT http://www.scribd.com/doc/3042648/192 http://www.scribd.com/doc/3025237/brilliance-iCT-technical-backgrounder Technology Backgrounder Computed Tomography (CT) A recognized leader in the industry, Philips offers a complete range of Computed Tomography (CT) products and services to meet the requirements of a wide variety of healthcare providers, from routine to cutting edge. Helping clinicians improve patient management by continually developing new applications and tools that save time to allow more focus on patients, Philips CT delivers new value through a deeper understanding of the way its customers need and want to work. These breakthroughs are made possible by being focused on designs that are use Mon, 19 May 2008 21:49:15 GMT http://www.scribd.com/doc/3025237/brilliance-iCT-technical-backgrounder http://www.scribd.com/doc/2994220/pdf *AbsorbaTack™ 5mm Absorbable Fixation Device DESCRIPTION The 5 mm AbsorbaTack™ device is a sterile, single use device for fixation of prosthetic material, such as mesh, to soft tissue. The tack is constructed of an absorbable synthetic polyester copolymer derived from lactic and glycolic acid. The device is offered with 5, 10 or 20 absorbable tacks. INDICATIONS The device is intended for fixation of prosthetic material to soft tissue in various minimally invasive and open surgical procedures such as hernia repair. CONTRAINDICATIONS The device is not intended for use when prosthetic material fi Fri, 16 May 2008 20:17:15 GMT http://www.scribd.com/doc/2994220/pdf http://www.scribd.com/doc/2972219/Vision-3D-Backgrounder BACKGROUNDER The Medtronic Vision 3D Portfolio Overview The Vision 3D™ wireless ICD and CRT-D portfolio offers unparalleled depth and breadth of unique clinical options that are built on our industry leading pacing and ICD exclusives. It is the industry’s most comprehensive family of wireless implantable heart devices. The portfolio brings together Medtronic’s state-of-the-art cardiac rhythm device technology to provide physicians and patients the devices, services and remote monitoring needed to meet individual therapy goals: • Increased Choice of Product – Device options built on industry-l Wed, 14 May 2008 17:43:27 GMT http://www.scribd.com/doc/2972219/Vision-3D-Backgrounder http://www.scribd.com/doc/2903542/PeakBrochure THE PULSE OF PRECISION. THE PEAK® SURGERY SYSTEM DELIVERS SUPERIOR CUTTING AND COAGULATION WITH MINIMAL THERMAL DAMAGE. �e PEAK Surgery System is not yet available in the U.S. PEAK Surgical is in the process of filing pre-market notification with the FDA. *Highly insulated electrode “With the PlasmaBlade, tissue looks healthier, with no char. �e thermal damage we typically see with traditional tools has been eliminated.” Kai Ihnken, M.D., Cardiothoracic Surgery Valley Medical Center, San Jose, CA PEAK Technology Overview �e PEAK Surgery System strikes a unique balance between precise cutting Wed, 07 May 2008 18:29:37 GMT http://www.scribd.com/doc/2903542/PeakBrochure http://www.scribd.com/doc/2903343/Peak5FBrochure5FrA THE PULSE OF PRECISION. THE PEAK® SURGERY SYSTEM DELIVERS SUPERIOR CUTTING AND COAGULATION WITH MINIMAL THERMAL DAMAGE. �e PEAK Surgery System is not yet available in the U.S. PEAK Surgical is in the process of filing pre-market notification with the FDA. *Highly insulated electrode “With the PlasmaBlade, tissue looks healthier, with no char. �e thermal damage we typically see with traditional tools has been eliminated.” Kai Ihnken, M.D., Cardiothoracic Surgery Valley Medical Center, San Jose, CA PEAK Technology Overview �e PEAK Surgery System strikes a unique balance between precise cutting Wed, 07 May 2008 18:09:37 GMT http://www.scribd.com/doc/2903343/Peak5FBrochure5FrA http://www.scribd.com/doc/2903115/Peak5FBrochure5FrA THE PULSE OF PRECISION. THE PEAK® SURGERY SYSTEM DELIVERS SUPERIOR CUTTING AND COAGULATION WITH MINIMAL THERMAL DAMAGE. �e PEAK Surgery System is not yet available in the U.S. PEAK Surgical is in the process of filing pre-market notification with the FDA. *Highly insulated electrode “With the PlasmaBlade, tissue looks healthier, with no char. �e thermal damage we typically see with traditional tools has been eliminated.” Kai Ihnken, M.D., Cardiothoracic Surgery Valley Medical Center, San Jose, CA PEAK Technology Overview �e PEAK Surgery System strikes a unique balance between precise cutting Wed, 07 May 2008 17:43:41 GMT http://www.scribd.com/doc/2903115/Peak5FBrochure5FrA http://www.scribd.com/doc/2547448/NIST20SP96019 practice guide recommended NIST Measurement Issues in Single Wall Carbon Nanotubes Stephen Freiman Stephanie Hooker Kalman Migler Sivaram Arepalli 960-19 National Institute of Standards and Technology U.S. Department of Commerce Special Publication 960-19 *NIST Recommended Practice Guide Special Publication 960-19 Measurement Issues in Single Wall Carbon Nanotubes Edited by: Stephen Freiman Stephanie Hooker Kalman Migler NIST Materials Science and Engineering Laboratory and Sivaram Arepalli NASA-DSC March 2008 U.S. Department of Commerce Carlos M. Gutierrez, Secretary National Institu Wed, 16 Apr 2008 05:16:58 GMT http://www.scribd.com/doc/2547448/NIST20SP96019 http://www.scribd.com/doc/2470946/080114-protaffin-technology-profile CellJammer® discovery technology ● Our Aim: To develop novel antiinflammatory biologicals by targeting endothelial surface glycan structures for the first time. ● Relevant Targets Relevant targets share property of binding to glycans (GAGs). Initial focus is on chemokines but with wider applications. ● Process Design and development of protein-based GAG antagonists, taking 6 months from start to in vivo characterisation. ● Advantages Faster development of specific therapeutics than with glycan-based drugs, easier manufacturing and specificity more easily achieved ● Business Model Pr Tue, 08 Apr 2008 17:25:57 GMT http://www.scribd.com/doc/2470946/080114-protaffin-technology-profile http://www.scribd.com/doc/2368752/Porphyrias Porphyrias Testing Click here for topics associated with this algorithm Abbreviations Disorders ADP Aminolevulinate dehydratase deficiency porphyria AIP Acute intermittent porphyria CEP Congenital erythropoietic porphyria EPP Erythropoietic protoporphyria HCP Hereditary coproporphyria HEP Hereditary erythropoietic porphyria PCT Porphyria cutanea tarda VP Variegate porphyria Analytes ALA Aminolevulinic acid PBG Porphobilinogen ZPP Zinc protoporphyrin INDICATIONS FOR TESTING Clinical suspicion for porphyrias Symptoms: Neurological Abdominal Consider acute porphyria AIP HCP VP PBG, Urine Quantit Thu, 27 Mar 2008 05:17:33 GMT http://www.scribd.com/doc/2368752/Porphyrias http://www.scribd.com/doc/2366027/6255 Contains Nonbinding Recommendations Draft — Not for Implementation Guidance for Industry Coronary Drug-Eluting Stents— Nonclinical and Clinical Studies DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 120 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit comments to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be ide Wed, 26 Mar 2008 17:15:59 GMT http://www.scribd.com/doc/2366027/6255 http://www.scribd.com/doc/2298418/ImpellaPercutaneousRevised Impella ® Circulatory Support System Percutaneous *Impella LP2.5 ® The Impella® LP2.5 is a minimally invasive percutaneous ventricular unloading catheter that allows the heart to rest and recover by: • Actively unloading the ventricle 9F 12F 2.5 L 5 DAYS LV Shaft diameter/ Pump motor diameter ® Impella • Reducing myocardial workload and oxygen consumption, while increasing cardiac output, coronary- and end-organ perfusion Quick and easy percutaneous insertion allows rapid positioning into the left ventricle. Thereafter, up to 2.5 liters of blood per minute are pumped from the l Mon, 17 Mar 2008 17:42:17 GMT http://www.scribd.com/doc/2298418/ImpellaPercutaneousRevised http://www.scribd.com/doc/2265703/TenasiTech20V1 TenasiTech Pty Ltd The Technology TenasiTech Pty Ltd is commercialising a materials science breakthrough that increases the strength of thermoplastic polyurethane elastomers whilst maintaining its flexibility. Themoplastic Elastomers with Superior Strength and Flexibility This technology was invented by Dr Darren Martin of the Australian Institute for Bioengineering and Nanotechnology. It is the first successful demonstration of TPU nanocomposites, reinforced with small amounts of synthetic clay particles. A number of novel TPU materials have been produced exhibiting the following physical pr Wed, 12 Mar 2008 17:25:25 GMT http://www.scribd.com/doc/2265703/TenasiTech20V1 http://www.scribd.com/doc/2223983/FENO-brochure-eng Improving Diagnosis and Management of Asthma through Feno Measurement d ale h Ex ti o na l Fe no Fr – ac N id ic Ox itr e *What is NO? Nitric oxide (NO) is produced in the epithelial cells of the bronchial wall as an intrinsic part of the inflammatory process. NO production has been shown to increase when there is eosinophilic airway inflammation1, 2. The presence of endogenous NO in exhaled air was first reported in 1991 by Gustafsson et al.3 and in 1993 Alving et al. found that NO in exhaled air was elevated in patients with asthma4. Since that time research has been directed at un Thu, 06 Mar 2008 00:19:53 GMT http://www.scribd.com/doc/2223983/FENO-brochure-eng http://www.scribd.com/doc/2187368/uLED-Overview Tyndall is developing micro-LED (µLED) devices as nextgeneration light sources for miniature lighting applications. Under an EI-funded project we are offering customer-specific prototypes to best suit the needs of Irish companies. The miniature light sources are ultra-efficient and designed to provide high brightness illumination in miniature situations. Miniaturisation of Light Sources 15µm Light Bulb LED 19 pixel µLED array (Tyndall) Example of a Handheld Diagnostic Device Features: • Maximum brightness across miniature objects • Minimal power consumption • Small physical dim Thu, 28 Feb 2008 14:03:38 GMT http://www.scribd.com/doc/2187368/uLED-Overview http://www.scribd.com/doc/2093514/Riegel20decision (Slip Opinion) OCTOBER TERM, 2007 Syllabus 1 NOTE: Where it is feasible, a syllabus (headnote) will be released, as is being done in connection with this case, at the time the opinion is issued. The syllabus constitutes no part of the opinion of the Court but has been prepared by the Reporter of Decisions for the convenience of the reader. See United States v. Detroit Timber & Lumber Co., 200 U. S. 321, 337. SUPREME COURT OF THE UNITED STATES Syllabus RIEGEL, INDIVIDUALLY AND AS ADMINISTRATOR OF ESTATE OF RIEGEL v. MEDTRONIC, INC. CERTIORARI TO THE UNITED STATES COURT OF APPEALS FOR THE S Wed, 20 Feb 2008 16:15:24 GMT http://www.scribd.com/doc/2093514/Riegel20decision http://www.scribd.com/doc/1041329/AVT AVT Ultra thin client advanced visualization *Advanced visualization at your fingertips Today, you need advanced visualization to get the most from your studies. However, until now you have not always been able to access it when and where you need it. AVT is a new advanced visualization solution that provides fast access anywhere, anytime. Forget the limits of the reading room. With AVT, advanced visualization is always at your fingertips. A true thin client A basic laptop or desktop computer, and a standard network connection or 2-4 Mbps broadband service: with AVT, that’s all you need to Fri, 18 Jan 2008 19:11:16 GMT http://www.scribd.com/doc/1041329/AVT http://www.scribd.com/doc/990754/BD-GeneOhm-MRSA BD GeneOhm MRSA ™ “Healthcare facilities must not accept ongoing Knowing how and when to treat a patient leads to better medicine Assay Performance 1 multidrug-resistant organism (MDRO) infection outbreaks…as the status quo. With selection of infection control measures appropriate to their situation, all facilities can achieve the desired goal and reduce the MDRO burden substantially.” - CDC/HICPAC, Management of MDROs in Healthcare Settings, 2006 Sensitivity ....................................................93% Specificity ....................................................96% Fri, 11 Jan 2008 20:09:13 GMT http://www.scribd.com/doc/990754/BD-GeneOhm-MRSA http://www.scribd.com/doc/907210/VVBrochure ON’T STICK D IN VAIN. TICK IN VEIN. S Whether due to age, skin tone or condition, veins can be significantly difficult to locate and access in many patients. VeinViewer by LuminetxTM uses unique, patented technologies to identify and locate subcutaneous veins and project their location directly onto the surface of the skin. “VeinViewer helps us to avoid multiple sticks.” - Richard A. Baum, MD, Chief of Interventional Radiology, Brigham and Women’s Hospital *INVIEW VE “Invention of the Year” - TIME Magazine ER BY LUMINE TX TM “Good news for patients and nurses” - NBC Los Fri, 14 Dec 2007 21:02:04 GMT http://www.scribd.com/doc/907210/VVBrochure http://www.scribd.com/doc/904616/VV-FeaturesD00210A N V I E W E R F E AT U R E S VEI Flexible Positioning: Handles allow you to position and aim the head wherever you need it. The arm extends horizontally for a range of up to forty inches. Also, it can glide up or down for a vertical range of approximately four feet. Push-Button Operation: Simple operating and imaging controls are all located on one panel. New Technology: VeinViewer employs near-infrared technology to reveal subcutaneous vascular structures. Mobile and Stable: The VeinViewer cart handle and wheel system allow for easy transport within a room or between departments. The wheel l Thu, 13 Dec 2007 17:36:26 GMT http://www.scribd.com/doc/904616/VV-FeaturesD00210A http://www.scribd.com/doc/710047/GLU-120407 DEVELOPMENT OF AN IMPLANTABLE GLUCOSE SENSOR Robert E. Carlson, Ph.D. President and Chief Science Officer RECEPTORS LLC Suite 510 / MD 57 1107 Hazeltine Blvd. Chaska, MN 55318 Voice: (952) 448-4337 FAX: (952) 448-1651 email: bc@receptorsllc.com WWW.RECEPTORSLLC.COM Scott R. Silverman Chairman and Chief Executive Officer VeriChip Corporation 1690 S. Congress Avenue, Suite 200 Delray Beach, FL 33445 Voice: (561) 805-8008 FAX: (561) 805-8001 email: ssilverman@verichipcorp.com www.verichipcorp.com Zeke Mejia Chief Technology Officer Digital Angel Corporation 490 Villaume Avenue St. Paul, MN 55075 Wed, 05 Dec 2007 06:12:07 GMT http://www.scribd.com/doc/710047/GLU-120407 http://www.scribd.com/doc/524328/AXIOM-Innovations-e-Nov-2007 AXIOM Innovations The Magazine for Interventional Angiography and Cardiology, Radiography and Fluoroscopy Edition 6/November 2007 Special RSNA Edition There’s so much more to zee Introducing the Artis zee Family Page 4 Ready for the Future Interview with Prof. Dr. Reiser Page 12 A Tradition of Innovations The Future of FD Technology Page 16 Artis zeego is 510k pending *Editorial Editorial Dear Reader, This year’s RSNA is special. A new era is about to begin. We not just talk about being innovative, we deliver innovations. We from the AX Division at Siemens Medical Solutions are proud Mon, 26 Nov 2007 21:02:57 GMT http://www.scribd.com/doc/524328/AXIOM-Innovations-e-Nov-2007 http://www.scribd.com/doc/449195/071017-synthetic-genomics-options SYNTHETIC GENOMICS | Options for Governance Michele S. Garfinkel, The J. Craig Venter Institute, Rockville, Maryland, Drew Endy, Massachusetts Institute of Technology, Cambridge, Massachusetts, Gerald L. Epstein, Center for Strategic and International Studies, Washington, District of Columbia and Robert M. Friedman, The J. Craig Venter Institute, Rockville, Maryland October 2007 Synthetic Genomics | Options for Governance 1 *The views and opinions expressed in this report are those of the authors and not necessarily those of the other study Core Group members, the participants of the work Wed, 31 Oct 2007 04:55:46 GMT http://www.scribd.com/doc/449195/071017-synthetic-genomics-options http://www.scribd.com/doc/440690/Nav-brochure-US GE Healthcare Navigate any case with ease. Navigator Applications Suite *The more clearly you can see, the more confidently you can decide. Clarity. Confidence. Insight. Trust. With an exclusive set of intelligent clinical tools – together for the first time ever – to help you most effectively address the clinical situation at hand. Navigator™ Applications Suite is a smart technology that analyzes drug therapy information to model and predict the effect of supported anesthesia-related drugs and drug interactions. It helps you determine effective treatment plans for each patient. And Mon, 29 Oct 2007 15:31:34 GMT http://www.scribd.com/doc/440690/Nav-brochure-US http://www.scribd.com/doc/416126/33-Philips-FIMI-ProScribe-12inch-Product-Introduction-v2-8 ProScribe 12” Mobile Display General introduction (part 1) Version 2.8 – April 2007 Eric van ‘t Hoff Business Development Manager Philips Medical Systems - FIMI Professional display solutions Eric.van.t.Hoff@Philips.com *Royal Philips Electronics Headquarters in Amsterdam, The Netherlands • Multinational workforce – 121.732 employees Medical Lighting • Global company – – – – 4 key divisions 60 different businesses Manufacturing in 28 countries Local presence in 150 countries Consumer Electronics Domestic Appliances • Performance 2006 – Sales € 27,B – Net In Wed, 24 Oct 2007 03:18:11 GMT http://www.scribd.com/doc/416126/33-Philips-FIMI-ProScribe-12inch-Product-Introduction-v2-8 http://www.scribd.com/doc/413007/hc-factsheet hemoCORM Company FactSheet Therapeutic focus CO-RMs have shown activity in numerous in vitro and in vivo preclinical models (list of publications available on request). hemoCORM’s current development focus is in transplantation, and the protection of tissues from ischaemic damage (e.g. after myocardial infarction or angioplasty). These represent significant, growing markets, in which there is great demand for new active substances. Mechanism of action The activity of hemoCORM’s compounds is consistent with their primary effects being caused by the release of CO. The best characterised rec Mon, 22 Oct 2007 14:28:59 GMT http://www.scribd.com/doc/413007/hc-factsheet http://www.scribd.com/doc/319915/4filed IOPtima 11. The Company 12. Glaucoma 13. The Technology 14. Background - Current Non-Penetrating Filtration Surgery (Trabeculectomy) 15. IOPtima’s Approach - CO2 Laser Filtration Surgery 16. Intellectual Property (IP) 17. Regulatory Pathway 18. The Market 19. Business Strategy 20. Development Status 21. Glaucoma Treatments – Comparison 22. Team 23. References The Company IOPtima Ltd. (IOPtima) focuses on the discovery, development and commercialization of its innovative and proprietary technologies for the treatment of Glaucoma – A common eye disease that might lead to loss of sight. IOP Fri, 21 Sep 2007 16:42:11 GMT http://www.scribd.com/doc/319915/4filed http://www.scribd.com/doc/297106/2007pressrelease 2007 LASKER AWARDS for MEDICAL RESEARCH EMBARGOED FOR RELEASE: For initial publication on Sunday, September 16, 2007 CONTACT: Kendall Christiansen Geto & de Milly, Inc. 212.686.4551; cell: 917.359.0725 Email: kchristiansen@getodemilly.com DISCOVERER OF DENDRITIC CELLS AND INVENTORS OF REPLACEMENT HEART VALVES RECEIVE LASKER AWARDS FOR MEDICAL RESEARCH ARCHITECT OF AIDS AND BIODEFENSE PROGRAMS HONORED WITH PUBLIC SERVICE AWARD NEW YORK, Sunday, September 16, 2007 – The 2007 Albert Lasker Medical Research Awards were announced today. Now celebrating their 62nd anniversary, the Lasker Awards Mon, 17 Sep 2007 05:46:25 GMT http://www.scribd.com/doc/297106/2007pressrelease http://www.scribd.com/doc/297051/2007pressrelease 2007 LASKER AWARDS for MEDICAL RESEARCH EMBARGOED FOR RELEASE: For initial publication on Sunday, September 16, 2007 CONTACT: Kendall Christiansen Geto & de Milly, Inc. 212.686.4551; cell: 917.359.0725 Email: kchristiansen@getodemilly.com DISCOVERER OF DENDRITIC CELLS AND INVENTORS OF REPLACEMENT HEART VALVES RECEIVE LASKER AWARDS FOR MEDICAL RESEARCH ARCHITECT OF AIDS AND BIODEFENSE PROGRAMS HONORED WITH PUBLIC SERVICE AWARD NEW YORK, Sunday, September 16, 2007 – The 2007 Albert Lasker Medical Research Awards were announced today. Now celebrating their 62nd anniversary, the Lasker Awards Mon, 17 Sep 2007 04:27:21 GMT http://www.scribd.com/doc/297051/2007pressrelease http://www.scribd.com/doc/283469/solid-cone-images **** Thu, 13 Sep 2007 15:52:17 GMT http://www.scribd.com/doc/283469/solid-cone-images http://www.scribd.com/doc/263978/Vigilance2 * Tue, 28 Aug 2007 17:01:14 GMT http://www.scribd.com/doc/263978/Vigilance2 http://www.scribd.com/doc/259213/HDe-1-5T-Brochure GE Healthcare Signa HDe 1.5T Capture what you could not capture before. *Smaller. Simpler. 30% less space. 7-day installation. 25% lower operating costs. A full menu of applications. Less than 5 patients per day to break even. If you’re first getting into MR, no system gets you there faster and more profitably than Signa HDe 1.5T. *Unmatched value Couple its low operating costs with its remarkable versatility, and Signa® HDe 1.5T makes solid financial sense – regardless of your patient volumes. Unsurpassed space savings With its compact footprint, Signa HDe 1.5T can be easily sited alm Wed, 22 Aug 2007 21:26:27 GMT http://www.scribd.com/doc/259213/HDe-1-5T-Brochure